{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:48:32Z","timestamp":1790005712329,"version":"4.0.1"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.psychres.2019.112583","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T11:25:19Z","timestamp":1569583519000},"page":"112583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The psychopharmacology algorithm project at the Harvard South Shore Program: An algorithm for adults with obsessive-compulsive disorder"],"prefix":"10.1016","volume":"281","author":[{"given":"Ashley M.","family":"Beaulieu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Tabasky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Osser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.psychres.2019.112583_bib0001","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/HRP.0000000000000098","article-title":"The psychopharmacology algorithm project at the Harvard South Shore Program: an algorithm for generalized anxiety disorder","volume":"24","author":"Abejuela","year":"2016","journal-title":"Harv. Rev. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2019.112583_bib0002","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1017\/S0033291799001270","article-title":"Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies","volume":"30","author":"Addis","year":"2000","journal-title":"Psychol. Med."},{"issue":"7","key":"10.1016\/j.psychres.2019.112583_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133591","article-title":"Deep brain stimulation for obsessive-compulsive disorder: a meta-analysis of treatment outcome and predictors of response","volume":"10","author":"Alonso","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.psychres.2019.112583_bib0004","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1994"},{"key":"10.1016\/j.psychres.2019.112583_bib0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"issue":"6","key":"10.1016\/j.psychres.2019.112583_bib0006","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/ajg.2014.82","article-title":"Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis","volume":"109","author":"Anglin","year":"2014","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.psychres.2019.112583_bib0007","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/10673220903523524","article-title":"The psychopharmacology algorithm project at the Harvard South Shore Program: an update on bipolar depression","volume":"18","author":"Ansari","year":"2010","journal-title":"Harv. Rev. Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2019.112583_bib0008","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3109\/10673229.2011.614483","article-title":"The psychopharmacology algorithm project at the Harvard South Shore Program: an update on posttraumatic stress disorder","volume":"19","author":"Bajor","year":"2011","journal-title":"Harv. Rev. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2019.112583_bib0009","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/JCP.0000000000000989","article-title":"Effectiveness of venlafaxine in selective serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: experience from a specialty clinic in India","volume":"39","author":"Balachander","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2019.112583_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psym.2012.11.001","article-title":"QTc prolongation, torsades de pointes, and psychotropic medications","volume":"54","author":"Beach","year":"2013","journal-title":"Psychosomatics"},{"issue":"5","key":"10.1016\/j.psychres.2019.112583_bib0011","doi-asserted-by":"crossref","first-page":"716","DOI":"10.4088\/JCP.09m05266gre","article-title":"Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder","volume":"72","author":"Berlin","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"8836","key":"10.1016\/j.psychres.2019.112583_bib0012","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0140-6736(93)92546-6","article-title":"Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine","volume":"341","author":"Bertilsson","year":"1993","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.psychres.2019.112583_bib0013","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1176\/appi.ajp.2013.13070905","article-title":"Cardiac safety concerns remain for citalopram at dosages above 40\u202fmg\/day","volume":"171","author":"Bird","year":"2014","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.psychres.2019.112583_bib0014","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/mp.2009.50","article-title":"Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder","volume":"15","author":"Bloch","year":"2010","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2019.112583_bib0015","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/tpj.2013.12","article-title":"Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder","volume":"14","author":"Brandl","year":"2014","journal-title":"Pharmacogen. J."},{"issue":"11","key":"10.1016\/j.psychres.2019.112583_bib0016","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1177\/0269881111431751","article-title":"Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study","volume":"26","author":"Bruno","year":"2012","journal-title":"J. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.psychres.2019.112583_bib0017","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/ijnp\/pyy079","article-title":"From treatment response to recovery: a realistic goal in OCD","volume":"21","author":"Burchi","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.psychres.2019.112583_bib0018","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/schbul\/sbu169","article-title":"Obsessive-Compulsive disorder, psychosis, and bipolarity: a longitudinal cohort and multigenerational family study","volume":"41","author":"Cederlof","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2019.112583_bib0019","series-title":"Obsessive-compulsive Symptoms in Schizophrenia","author":"De Haan","year":"2015"},{"issue":"6","key":"10.1016\/j.psychres.2019.112583_bib0020","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.psym.2014.01.010","article-title":"Antidepressants and the risk of hyponatremia: a class-by-class review of literature","volume":"55","author":"De Picker","year":"2014","journal-title":"Psychosomatics"},{"issue":"6","key":"10.1016\/j.psychres.2019.112583_bib0021","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/01.jcp.0000095342.32154.54","article-title":"A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder","volume":"23","author":"Denys","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.psychres.2019.112583_bib0022","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/JCP.0b013e3182367aee","article-title":"A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder","volume":"31","author":"Diniz","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2019.112583_bib0023","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jad.2015.04.054","article-title":"Antidepressants worsen rapid-cycling course in bipolar depression: a step-BD randomized clinical trial","volume":"184","author":"El-Mallakh","year":"2015","journal-title":"J. Affect. Disord."},{"issue":"8","key":"10.1016\/j.psychres.2019.112583_bib0024","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/pcn.12394","article-title":"Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study","volume":"70","author":"Emamzadehfard","year":"2016","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"11","key":"10.1016\/j.psychres.2019.112583_bib0025","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/pcn.12430","article-title":"Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: a placebo-controlled, double-blind, randomized trial","volume":"70","author":"Esalatmanesh","year":"2016","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"11","key":"10.1016\/j.psychres.2019.112583_bib0026","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4088\/JCP.v61n1109","article-title":"Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment","volume":"61","author":"Fava","year":"2000","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2019.112583_bib0027","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1461145704004675","article-title":"Evidence-based pharmacotherapy of obsessive-compulsive disorder","volume":"8","author":"Fineberg","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2019.112583_bib0028","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.psychres.2014.12.003","article-title":"Obsessive-compulsive disorder (OCD): practical strategies for pharmacological and somatic treatment in adults","volume":"227","author":"Fineberg","year":"2015","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.psychres.2019.112583_bib0029","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1176\/appi.ajp.162.1.151","article-title":"Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder","volume":"162","author":"Foa","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2019.112583_bib0030","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jpsychires.2012.09.015","article-title":"Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study","volume":"47","author":"Ghaleiha","year":"2013","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.psychres.2019.112583_bib0031","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/HRP.0000000000000197","article-title":"The psychopharmacology algorithm project at the Harvard South Shore Program: an update on unipolar nonpsychotic depression","volume":"27","author":"Giakoumatos","year":"2019","journal-title":"Harv. Rev. Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2019.112583_bib0032","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jama.288.6.701","article-title":"Sertraline treatment of major depression in patients with acute MI or unstable angina","volume":"288","author":"Glassman","year":"2002","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.psychres.2019.112583_bib0033","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004850-199506000-00001","article-title":"A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder","volume":"10","author":"Greist","year":"1995","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2019.112583_bib0034","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.psychres.2016.09.031","article-title":"Induced Obsessive Compulsive Symptoms (OCS) in schizophrenia patients under atypical 2 antipsychotics (AAPs): review and hypotheses","volume":"246","author":"Grillault Laroche","year":"2016","journal-title":"Psychiatry Res."},{"issue":"1\u201302","key":"10.1016\/j.psychres.2019.112583_bib0035","first-page":"5","article-title":"Editorial to consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology","volume":"51","author":"Grunder","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2019.112583_bib0036","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00213-013-3067-z","article-title":"In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)","volume":"228","author":"Haghighi","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.psychres.2019.112583_bib0037","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/10673220802277904","article-title":"The psychopharmacology algorithm project at the Harvard South Shore Program: an update on psychotic depression","volume":"16","author":"Hamoda","year":"2008","journal-title":"Harv. Rev. Psychiatry"},{"issue":"8","key":"10.1016\/j.psychres.2019.112583_bib0038","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/2047-783X-14-8-367","article-title":"Maintenance electroconvulsive therapy for comorbid pharmacotherapy-refractory obsessive-compulsive and schizoaffective disorder","volume":"14","author":"Hanisch","year":"2009","journal-title":"Eur. J. Med. Res."},{"issue":"6","key":"10.1016\/j.psychres.2019.112583_bib0039","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/YIC.0000000000000043","article-title":"Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder","volume":"29","author":"Heidari","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"7565","key":"10.1016\/j.psychres.2019.112583_bib0040","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/bmj.333.7565.424","article-title":"Obsessive-compulsive disorder","volume":"333","author":"Heyman","year":"2006","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.psychres.2019.112583_bib0041","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00737-015-0542-z","article-title":"Obsessive-compulsive disorder in pregnancy and the postpartum period: course of illness and obstetrical outcome","volume":"19","author":"House","year":"2016","journal-title":"Arch. Womens Ment. Health"},{"issue":"2","key":"10.1016\/j.psychres.2019.112583_bib0042","first-page":"104","article-title":"Lamotrigine augmentation versus placebo in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder: a randomized controlled trial","volume":"11","author":"Khalkhali","year":"2016","journal-title":"Iran J. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112583_bib0043","doi-asserted-by":"crossref","first-page":"d8012","DOI":"10.1136\/bmj.d8012","article-title":"Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries","volume":"344","author":"Kieler","year":"2012","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.psychres.2019.112583_bib0044","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1176\/ajp.153.11.1450","article-title":"Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?","volume":"153","author":"Koran","year":"1996","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2019.112583_bib0045","first-page":"216","article-title":"Intravenous clomipramine for obsessive-compulsive disorder","volume":"14","author":"Koran","year":"1994","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.psychres.2019.112583_bib0046","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4088\/JCP.v66n0415","article-title":"Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation","volume":"66","author":"Koran","year":"2005","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2019.112583_bib0047","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1176\/appi.ajp.159.1.88","article-title":"Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder","volume":"159","author":"Koran","year":"2002","journal-title":"Am. J. Psychiatry"},{"issue":"3\u20134","key":"10.1016\/j.psychres.2019.112583_bib0048","first-page":"e31","article-title":"Radiosurgery for the treatment of psychiatric disorders: a review","volume":"80","author":"Leveque","year":"2013","journal-title":"World Neurosurg."},{"issue":"9","key":"10.1016\/j.psychres.2019.112583_bib0049","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamapsychiatry.2014.1193","article-title":"Gamma ventral capsulotomy for obsessive-compulsive disorder: a randomized clinical trial","volume":"71","author":"Lopes","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"Suppl","key":"10.1016\/j.psychres.2019.112583_bib0050","first-page":"1","article-title":"The expert consensus guideline series: treatment of obsessive-compulsive disorder","volume":"58","author":"March","year":"1997","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2019.112583_bib0051","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1517\/14740330802423168","article-title":"Paroxetine: safety and tolerability issues","volume":"7","author":"Marks","year":"2008","journal-title":"Expert Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.psychres.2019.112583_bib0052","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4088\/JCP.08m04369","article-title":"A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder","volume":"70","author":"Matsunaga","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.psychres.2019.112583_bib0053","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S2215-0366(16)30264-4","article-title":"Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials","volume":"3","author":"McGirr","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"10","key":"10.1016\/j.psychres.2019.112583_bib0054","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jama.2013.107828","article-title":"Selective serotonin reuptake inhibitors for stroke recovery","volume":"310","author":"Mead","year":"2013","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.psychres.2019.112583_bib0055","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jamapsychiatry.2014.1011","article-title":"Obsessive-compulsive disorder as a risk factor for schizophrenia: a nationwide study","volume":"71","author":"Meier","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.psychres.2019.112583_bib0056","series-title":"The Clozapine Handbook","author":"Meyer","year":"2019"},{"issue":"5","key":"10.1016\/j.psychres.2019.112583_bib0057","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/HRP.0000000000000018","article-title":"The psychopharmacology algorithm project at the Harvard South Shore Program: an algorithm for acute mania","volume":"22","author":"Mohammad","year":"2014","journal-title":"Harv. Rev. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2019.112583_bib0058","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00004850-200103000-00002","article-title":"Citalopram 20\u202fmg, 40\u202fmg and 60\u202fmg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder","volume":"16","author":"Montgomery","year":"2001","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.psychres.2019.112583_bib0059","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jagp.2016.08.008","article-title":"Non-tricyclic and non-selective serotonin reuptake inhibitor antidepressants and recurrent falls in frail older women","volume":"24","author":"Naples","year":"2016","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2019.112583_bib0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v67n0103","article-title":"High-Dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial","volume":"67","author":"Ninan","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2019.112583_bib0061","first-page":"179","article-title":"Drug interactions in augmentation strategies for pharmacotherapy of OCD","volume":"5","author":"Oesterheld","year":"1999","journal-title":"J. Pract. Psychiatry Behav. Health"},{"issue":"12","key":"10.1016\/j.psychres.2019.112583_bib0062","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/01.IDT.0000391328.04097.1e","article-title":"The psychopharmacology algorithm project at the Harvard South Shore Program an update on generalized social anxiety disorder","volume":"45","author":"Osser","year":"2010","journal-title":"Psychopharm. Rev."},{"issue":"1","key":"10.1016\/j.psychres.2019.112583_bib0063","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/HRP.0b013e31827fd915","article-title":"The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia","volume":"21","author":"Osser","year":"2013","journal-title":"Harv. Rev. Psychiatry"},{"issue":"11","key":"10.1016\/j.psychres.2019.112583_bib0064","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1176\/appi.ajp.2013.13020185","article-title":"The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders","volume":"170","author":"Pacchiarotti","year":"2013","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.psychres.2019.112583_bib0065","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.4088\/JCP.v65n1015","article-title":"Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study","volume":"65","author":"Pallanti","year":"2004","journal-title":"J. Clin. Psychiatry"},{"issue":"10","key":"10.1016\/j.psychres.2019.112583_bib0066","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1177\/0269881109104850","article-title":"High-dose selective serotonin reuptake inhibitors in OCD: a systematic retrospective case notes survey","volume":"24","author":"Pampaloni","year":"2010","journal-title":"J. Psychopharmacol."},{"issue":"7516","key":"10.1016\/j.psychres.2019.112583_bib0067","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/bmj.331.7516.529","article-title":"SSRIs and gastrointestinal bleeding","volume":"331","author":"Paton","year":"2005","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.psychres.2019.112583_bib0068","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/jcpt.12370","article-title":"N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial","volume":"41","author":"Paydary","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.psychres.2019.112583_bib0069","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1345\/aph.1E362","article-title":"The role of venlafaxine in the treatment of obsessive-compulsive disorder","volume":"39","author":"Phelps","year":"2005","journal-title":"Ann. Pharmacother."},{"issue":"3","key":"10.1016\/j.psychres.2019.112583_bib0070","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00004714-199206000-00002","article-title":"A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder","volume":"12","author":"Pigott","year":"1992","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2019.112583_bib0071","first-page":"167","article-title":"Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs)","volume":"32","author":"Ravizza","year":"1996","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.psychres.2019.112583_bib0072","doi-asserted-by":"crossref","first-page":"h3190","DOI":"10.1136\/bmj.h3190","article-title":"Specific SSRIs and birth defects: bayesian analysis to interpret new data in the context of previous reports","volume":"351","author":"Reefhuis","year":"2015","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.psychres.2019.112583_bib0073","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/npp.2013.150","article-title":"Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept","volume":"38","author":"Rodriguez","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.psychres.2019.112583_bib0074","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/archpsyc.65.8.914","article-title":"Capsulotomy for obsessive-compulsive disorder: long-term follow-up of 25 patients","volume":"65","author":"Ruck","year":"2008","journal-title":"Arch. Gen. Psychiatry"},{"issue":"11","key":"10.1016\/j.psychres.2019.112583_bib0075","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2019.112583_bib0076","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/JCP.0000000000000651","article-title":"Memantine as an adjuvant treatment for obsessive compulsive symptoms in manic phase of bipolar disorder: a randomized, double-blind, placebo-controlled clinical trial","volume":"37","author":"Sahraian","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.psychres.2019.112583_bib0077","first-page":"10","article-title":"SNRIs pharmacological alternatives for the treatment of obsessive compulsive disorder?","volume":"8","author":"Sansone","year":"2011","journal-title":"Innov. Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.psychres.2019.112583_bib0078","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.psychres.2011.01.019","article-title":"A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder","volume":"189","author":"Sayyah","year":"2011","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.psychres.2019.112583_bib0079","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00406-018-0884-4","article-title":"Obsessive-compulsive symptoms in psychotic disorders: longitudinal associations of symptom clusters on between- and within-subject levels","volume":"269","author":"Schirmbeck","year":"2019","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.psychres.2019.112583_bib0080","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/ebmh.8.2.42","article-title":"Mirtazapine plus citalopram has short term but not longer term benefits over citalopram alone for the symptoms of obsessive compulsive disorder","volume":"8","author":"Schule","year":"2005","journal-title":"Evid. Based Ment. Health"},{"issue":"1","key":"10.1016\/j.psychres.2019.112583_bib0081","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/hup.1169","article-title":"The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study","volume":"26","author":"Selvi","year":"2011","journal-title":"Hum. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.psychres.2019.112583_bib0082","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/JCP.0b013e3181a5233f","article-title":"Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis","volume":"29","author":"Serretti","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.psychres.2019.112583_bib0083","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/hup.1145","article-title":"A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder","volume":"25","author":"Soltani","year":"2010","journal-title":"Hum. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.psychres.2019.112583_bib0084","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1185\/030079907X178838","article-title":"Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study","volume":"23","author":"Stein","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"issue":"3","key":"10.1016\/j.psychres.2019.112583_bib0085","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11920-012-0268-9","article-title":"A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder","volume":"14","author":"Stein","year":"2012","journal-title":"Curr. Psychiatry Rep."},{"issue":"3","key":"10.1016\/j.psychres.2019.112583_bib0086","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2165\/00139709-200524030-00013","article-title":"Tricyclic antidepressant poisoning : cardiovascular toxicity","volume":"24","author":"Thanacoody","year":"2005","journal-title":"Toxicol. Rev."},{"issue":"11","key":"10.1016\/j.psychres.2019.112583_bib0087","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/archpsyc.1980.01780240079009","article-title":"Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial","volume":"37","author":"Thoren","year":"1980","journal-title":"Arch. Gen. Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2019.112583_bib0088","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/archpsyc.1994.03950070051010","article-title":"A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder","volume":"51","author":"Tollefson","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2019.112583_bib0089","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/YCT.0000000000000335","article-title":"Transcranial magnetic stimulation for obsessive-compulsive disorder: an updated systematic review and meta-analysis","volume":"32","author":"Trevizol","year":"2016","journal-title":"J. ect"},{"issue":"1","key":"10.1016\/j.psychres.2019.112583_bib0090","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.genhosppsych.2014.10.011","article-title":"Weight gain and associated factors in patients using newer antidepressant drugs","volume":"37","author":"Uguz","year":"2015","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112583_bib0091","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12888-014-0317-5","article-title":"Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis","volume":"14","author":"Veale","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2019.112583_bib0092","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4088\/JCP.v66n0211","article-title":"Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study","volume":"66","author":"Vulink","year":"2005","journal-title":"J. Clin. Psychiatry"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178119313629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178119313629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:38:16Z","timestamp":1759037896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178119313629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":92,"alternative-id":["S0165178119313629"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2019.112583","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The psychopharmacology algorithm project at the Harvard South Shore Program: An algorithm for adults with obsessive-compulsive disorder","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2019.112583","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112583"}}